Overview

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and tolerability of single doses of odanacatib (MK0822) when administered with a light breakfast.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.